Premium
Optimalization of erythropoietin administration: an Asian perspective
Author(s) -
LUI SIU FAI
Publication year - 1996
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.1996.tb00173.x
Subject(s) - medicine , erythropoietin , administration (probate law) , perspective (graphical) , intensive care medicine , pharmacology , political science , law , artificial intelligence , computer science
Summary: The efficacy and benefits of recombinant human erythropoietin (r‐HuEPO) in the treatment of renal anaemia are well established. Because r‐HuEPO therapy is expensive, it is important to optimize its use. It is acceptable to start with a moderate dosage and aim for a moderate rate of response in order to avoid side effects and to reduce costs. the optimal haemoglobin level should be around 12 g/dL; however, in practice, this is often limited to 10 g/dL. Response rate should be around 1 g/dL per month. Subcutaneous administration is the most optimal route and it can be given once or twice weekly.